Labcorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
6 - 10 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Whole blood or LabCorp buccal swab kit (buccal swab collection kit contains instructions for use of a buccal swab)
7 mL whole blood or LabCorp buccal swab kit
3 mL whole blood or two buccal swabs
Lavender-top (EDTA) tube, yellow-top (ACD) tube, or LabCorp buccal swab kit
Maintain specimen at room temperature or refrigerate at 4°C.
Frozen specimen; hemolysis; quantity not sufficient for analysis; improper container; one buccal swab; wet buccal swab
Variability in response (efficacy and toxicity) to 5-fluorouracil (5-FU) chemotherapy has been linked to the rate-limiting enzyme in the drug's catabolic pathway, known as dihydropyrimidine dehydrogenase (DPD).
This procedure will only detect the presence of the wild type or mutant allele for the DPD IVS14+1G>A mutation.
This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.
Polymerase chain reaction (PCR); restriction enzyme digestion; gel electrophoresis
DPD deficiency results in excessive amounts of 5-FU available to be anabolized to its active metabolite and is relatively undetectable by clinical observation prior to 5-FU administration. Extensive studies have associated both profound and partial deficiency in DPD activity with severe unanticipated toxicity after 5-FU administration. Numerous studies genotyping DPD deficient patients, their family members, and healthy individuals have shown that the splice-site mutation (IVS14+1G>A) is the most characterized and frequently observed allele associated with decreased DPD enzyme activity. Screening for the presence of this mutation in the Caucasian population showed frequencies of 0.91% homozygous and 1.8% heterozygous for the IVS14+1G>A allele.
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|511176||DPD 5-Fluorouracil Toxicity||511186||Result:||45284-7|
|511176||DPD 5-Fluorouracil Toxicity||511235||Mutation:||N/A|
|511176||DPD 5-Fluorouracil Toxicity||511189||Director Review:||72486-4|
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf